1-deoxynojirimycin has been researched along with interleukin-8 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berton, G; Bezzerri, V; Cabrini, G; Cioffi, F; Dechecchi, MC; Gambari, R; Huang, S; Lampronti, I; Mazzi, P; Nicolis, E; Scupoli, MT; Wiszniewski, L | 1 |
Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
1 trial(s) available for 1-deoxynojirimycin and interleukin-8
Article | Year |
---|---|
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
1 other study(ies) available for 1-deoxynojirimycin and interleukin-8
Article | Year |
---|---|
Modulators of sphingolipid metabolism reduce lung inflammation.
Topics: 1-Deoxynojirimycin; Amitriptyline; Animals; Anti-Inflammatory Agents; Cell Line; Ceramides; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation Mediators; Interleukin-8; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Pneumonia; Pseudomonas aeruginosa; Respiratory Mucosa | 2011 |